Spero Q3 Loss Widens to $44.3M on $35M SP001 Upfront; Cash of $107.9M Funds Runway Into 2H 2029
SPRO is trading near its 52-week low of $0.961 (3.0% above the low).
Summary
Spero's $44.3 million third-quarter loss was driven by a $35.0 million non-cash IPR&D charge for the SP001 license, leaving $107.9 million of cash and a runway into the second half of 2029. The balance sheet is now dominated by the $103.0 million HCRx royalty financing liability.
Key Events · Earnings and Guidance · SPRO
-
Q3 Loss Widens on IPR&D Charge
Net loss was $44.3 million for the three months ended September 30, 2026 versus $7.4 million a year earlier, including $35.0 million of acquired in-process research and development expense from the Innovent SP001 upfront payment made in August 2026.
-
Cash of $107.9M, Runway to 2H 2029
Cash and cash equivalents stood at $107.9 million at September 30, 2026, up from $40.3 million at December 31, 2025, after $103.2 million of net proceeds from the HCRx milestone and royalty financing; management states funding lasts into the second half of 2029.
-
Balance Sheet Now Liability-Heavy
Total liabilities of $109.2 million against total stockholders' equity of $0.8 million, with $50.8 million of the $103.0 million HCRx liability classified current and $52.3 million non-current.
-
SP001 Phase 2 Guided to Q2 2027
Subject to FDA clearance of the U.S. IND, Spero expects to advance SP001 into a Phase 2 trial in IgG4-RD patients in the second quarter of 2027; the Innovent agreement requires an IND filing within 12 months of the July 8, 2026 deal.
Analysis · SPRO · Life Sciences
The headline loss looks alarming next to last year's $7.4 million, but $35.0 million of it is a one-time accounting charge for the August payment to Innovent for the SP001 license, not cash burned on operations. What actually matters is the balance sheet: $107.9 million of cash plus a stated runway into the second half of 2029 buys roughly three years to get SP001 into and through its planned Phase 2 in IgG4-related disease, expected in the second quarter of 2027 subject to FDA clearing the IND. The offset is that the company is now almost entirely financed by borrowed-against-royalty money: total liabilities of $109.2 million against just $0.8 million of stockholders' equity, with the $103.0 million HCRx liability consuming 65% of future Utebzi proceeds after the notes are repaid. No ATM shares have been sold, so the $100 million Jefferies facility remains pure overhang rather than realized dilution.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SPRO was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.2M. The 52-week trading range was $0.96 to $3.08. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.